Cargando…
Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
Ipilimumab plus nivolumab therapy is approved for patients with unresectable advanced esophageal squamous cell carcinoma (ESCC). Although a combination of immune checkpoint inhibitors (ICIs), compared to conventional chemotherapy, can improve overall survival in patients with advanced ESCC, this inc...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518453/ https://www.ncbi.nlm.nih.gov/pubmed/37753079 http://dx.doi.org/10.3389/fimmu.2023.1259071 |
_version_ | 1785109517202096128 |
---|---|
author | Nakamura, Hajime Shionoya, Aika Arihara, Yohei Hayasaka, Naotaka Kubo, Tomohiro Usami, Makoto Sugita, Shintaro Uhara, Hisashi Takada, Kohichi |
author_facet | Nakamura, Hajime Shionoya, Aika Arihara, Yohei Hayasaka, Naotaka Kubo, Tomohiro Usami, Makoto Sugita, Shintaro Uhara, Hisashi Takada, Kohichi |
author_sort | Nakamura, Hajime |
collection | PubMed |
description | Ipilimumab plus nivolumab therapy is approved for patients with unresectable advanced esophageal squamous cell carcinoma (ESCC). Although a combination of immune checkpoint inhibitors (ICIs), compared to conventional chemotherapy, can improve overall survival in patients with advanced ESCC, this increases the incidence of immune-related adverse events (irAEs). Here, we describe an ESCC case that developed pemphigus vulgaris (PV), an extremely rare cutaneous irAE, during ipilimumab plus nivolumab treatment. The patient achieved a partial response to treatment. The PV was successfully managed after the cessation of ipilimumab and the use of a topical steroid. We should thus re-treat ESCC with nivolumab monotherapy. In the era of ICIs as standard cancer therapeutics, diagnostic criteria for blistering diseases need to be established to properly manage patients with cutaneous irAEs. |
format | Online Article Text |
id | pubmed-10518453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105184532023-09-26 Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review Nakamura, Hajime Shionoya, Aika Arihara, Yohei Hayasaka, Naotaka Kubo, Tomohiro Usami, Makoto Sugita, Shintaro Uhara, Hisashi Takada, Kohichi Front Immunol Immunology Ipilimumab plus nivolumab therapy is approved for patients with unresectable advanced esophageal squamous cell carcinoma (ESCC). Although a combination of immune checkpoint inhibitors (ICIs), compared to conventional chemotherapy, can improve overall survival in patients with advanced ESCC, this increases the incidence of immune-related adverse events (irAEs). Here, we describe an ESCC case that developed pemphigus vulgaris (PV), an extremely rare cutaneous irAE, during ipilimumab plus nivolumab treatment. The patient achieved a partial response to treatment. The PV was successfully managed after the cessation of ipilimumab and the use of a topical steroid. We should thus re-treat ESCC with nivolumab monotherapy. In the era of ICIs as standard cancer therapeutics, diagnostic criteria for blistering diseases need to be established to properly manage patients with cutaneous irAEs. Frontiers Media S.A. 2023-09-11 /pmc/articles/PMC10518453/ /pubmed/37753079 http://dx.doi.org/10.3389/fimmu.2023.1259071 Text en Copyright © 2023 Nakamura, Shionoya, Arihara, Hayasaka, Kubo, Usami, Sugita, Uhara and Takada https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Nakamura, Hajime Shionoya, Aika Arihara, Yohei Hayasaka, Naotaka Kubo, Tomohiro Usami, Makoto Sugita, Shintaro Uhara, Hisashi Takada, Kohichi Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review |
title | Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review |
title_full | Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review |
title_fullStr | Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review |
title_full_unstemmed | Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review |
title_short | Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review |
title_sort | pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518453/ https://www.ncbi.nlm.nih.gov/pubmed/37753079 http://dx.doi.org/10.3389/fimmu.2023.1259071 |
work_keys_str_mv | AT nakamurahajime pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview AT shionoyaaika pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview AT ariharayohei pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview AT hayasakanaotaka pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview AT kubotomohiro pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview AT usamimakoto pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview AT sugitashintaro pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview AT uharahisashi pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview AT takadakohichi pemphigusvulgarisasanimmunerelatedadverseeventinrecurrentmetastaticesophagealsquamouscellcarcinomatreatedwithipilimumabplusnivolumabacasereportandliteraturereview |